The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ⅱ, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastroesophageal junction cancer: B-RAX trial (JACCRO GC-09).
 
Takahisa Suzuki
No Relationships to Disclose
 
Naoki Izawa
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Ryohei Kawabata
Research Funding - Daiichi Sankyo/UCB Japan (Inst)
 
Kazuhiro Nishikawa
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo; EA Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Masazumi Takahashi
No Relationships to Disclose
 
Masato Nakamura
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Atsushi Ishiguro
No Relationships to Disclose
 
Hiroo Katsuya
No Relationships to Disclose
 
Jun Hihara
No Relationships to Disclose
 
Dai Manaka
No Relationships to Disclose
 
Yuji Negoro
No Relationships to Disclose
 
Mizutomo Azuma
Speakers' Bureau - Taiho Pharmaceutical
 
Akihito Tsuji
Speakers' Bureau - Bristol-Myers Squibb Corporation; Chugai Pharma; Lilly Japan; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Mitsugu Kochi
No Relationships to Disclose
 
Takao Takahashi
No Relationships to Disclose
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck KGaA; Ono Pharmaceutical; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hirofumi Michimae
No Relationships to Disclose
 
Yu Sunakawa
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck; MSD K.K; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Merck; MSD K.K
Research Funding - Chugai Pharma; Lilly Japan; Nihonkayaku; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda
 
Wataru Ichikawa
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Merck Serono; Nihonkayaku; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masashi Fujii
Travel, Accommodations, Expenses - Japan Clinical Cancer Research Organization